These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782 [TBL] [Abstract][Full Text] [Related]
3. Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment. Berthiaume JM; Wallace KB Cardiovasc Toxicol; 2007; 7(3):178-91. PubMed ID: 17901561 [TBL] [Abstract][Full Text] [Related]
4. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Sorokina N; O'Donnell JM; McKinney RD; Pound KM; Woldegiorgis G; LaNoue KF; Ballal K; Taegtmeyer H; Buttrick PM; Lewandowski ED Circulation; 2007 Apr; 115(15):2033-41. PubMed ID: 17404155 [TBL] [Abstract][Full Text] [Related]
5. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298 [TBL] [Abstract][Full Text] [Related]
8. Unravelling the metabolic rewiring in the context of doxorubicin-induced cardiotoxicity: Fuel preference changes from fatty acids to glucose oxidation. Guerra G; Russo M; Priolo R; Riganti C; Reano S; Filigheddu N; Hirsch E; Ghigo A Vascul Pharmacol; 2024 Jun; 155():107324. PubMed ID: 38985581 [TBL] [Abstract][Full Text] [Related]
9. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study. Jucker BM; Yang D; Casey WM; Olzinski AR; Williams C; Lenhard SC; Legos JJ; Hawk CT; Sarkar SK; Newsholme SJ Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1256-64. PubMed ID: 17726146 [TBL] [Abstract][Full Text] [Related]
10. How to protect doxorubicin-induced cardiomyopathy in male albino rats? Shaker O; Sourour DA J Cardiovasc Pharmacol; 2010 Mar; 55(3):262-8. PubMed ID: 20051877 [TBL] [Abstract][Full Text] [Related]
11. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. Mohamed HE; Asker ME; Ali SI; el-Fattah TM J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041 [TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947 [TBL] [Abstract][Full Text] [Related]